Mirixa Australia Achieves Six Month MilestonesOver 40% of pharmacies nationwide now enrolled; technology-backed, pharmacist-delivered programs launched to assist patients in adhering to six common chronic care medications Reston, Virginia and Sydney, Australia (November 17, 2009) – Mirixa Corporation, the leader in pharmacy-based patient care services and the Pharmacy Guild of Australia, the peak body representing owners of pharmacies across Australia, announced today results of the first six months of operating activity of Mirixa Australia. In less than two full quarters of operation, Mirixa Australia has successfully engaged over 40% of all pharmacies nationwide, enabling the delivery of patient care services via the customized Australian version of the MirixaPro℠ clinical platform. Mirixa Australia, a subsidiary of the Pharmacy Guild of Australia, now operates patient medication adherence programs, delivered person-to-person at community pharmacy, for both brand and generic medications. Current Australian programs include GSK’s Seretide, Pfizer’s Lipitor, and generic simvastatin, pravastatin, omeprazole and sertraline medicines offered by Australia’s three largest generic medicine distributors, namely Alphapharm, Apotex and Sigma. Programs generally target those patients whose MedsIndex score falls below 70 – an indicator of sub-optimal adherence. The Pharmacy Guild of Australia created and introduced MedsIndex in 2007, and with the help of the Mirixa U.S. team, integrated this score into programs offered through the MirixaPro clinical platform in Australia. “We’re quite proud of what our Australian pharmacy colleagues have accomplished over a very short span of time,” said Rick Solano, President and Chief Executive Officer of Mirixa. “The growth rate achieved by Mirixa Australia and its pharmacy partners is truly impressive. They are well on their way to establishing a national pharmacy network to deliver meaningful patient care services similar to what we’ve achieved here in the U.S.,” added Mr. Solano. Analysis of data by Mirixa Australia across all programs for one of its pilot network pharmacies revealed that after only 12 weeks of program implementation, over 60% of patients had an improvement in medication adherence as measured by their MedsIndex score, and the average adherence improvement across all enrolled patients exceeded 25 percent. “Medication non-adherence both here in Australia and worldwide represents a key source of both excess cost and suboptimal health outcomes,” noted Kos Sclavos, National President of the Pharmacy Guild of Australia. “While we’re still early in the game, we’re very pleased with the results we’re seeing. We have been waiting to see the 12 week result which coincides with the second patient consultation and these results exceed our expectation. The MedsIndex trend measured thus far encourages us that we’re on the right track. We applaud the pharmacies and program sponsors who have come along with us on this journey to pioneer and prove a new model for pharmacy delivered services across Australia – and encourage others to join their colleagues in this national effort to demonstrate the profound and positive impact pharmacists can have in improving patient care outcomes,” added Mr. Sclavos. About Mirixa About The Pharmacy Guild of Australia |
